nodes	percent_of_prediction	percent_of_DWPC	metapath
Plerixafor—CXCR4—Binding and entry of HIV virion—CD4—cervical cancer	0.0942	0.262	CbGpPWpGaD
Plerixafor—CXCR4—epithelium—cervical cancer	0.0698	0.111	CbGeAlD
Plerixafor—CXCR4—uterine cervix—cervical cancer	0.0692	0.11	CbGeAlD
Plerixafor—CXCR4—decidua—cervical cancer	0.0659	0.105	CbGeAlD
Plerixafor—CXCR4—renal system—cervical cancer	0.0647	0.103	CbGeAlD
Plerixafor—CXCR4—endometrium—cervical cancer	0.0626	0.0999	CbGeAlD
Plerixafor—CXCR4—mammalian vulva—cervical cancer	0.0606	0.0966	CbGeAlD
Plerixafor—CXCR4—uterus—cervical cancer	0.0577	0.092	CbGeAlD
Plerixafor—CXCR4—female reproductive system—cervical cancer	0.0519	0.0827	CbGeAlD
Plerixafor—CXCR4—female gonad—cervical cancer	0.0472	0.0753	CbGeAlD
Plerixafor—CXCR4—vagina—cervical cancer	0.0469	0.0748	CbGeAlD
Plerixafor—CXCR4—HIF-1-alpha transcription factor network—CA9—cervical cancer	0.0384	0.107	CbGpPWpGaD
Plerixafor—CXCR4—Early Phase of HIV Life Cycle—CD4—cervical cancer	0.0346	0.0961	CbGpPWpGaD
Plerixafor—CXCR4—lymph node—cervical cancer	0.0303	0.0484	CbGeAlD
Plerixafor—CXCR4—Hematopoietic Stem Cell Differentiation—NOTCH1—cervical cancer	0.02	0.0555	CbGpPWpGaD
Plerixafor—CXCR4—Cardiac Progenitor Differentiation—NOTCH1—cervical cancer	0.0159	0.0443	CbGpPWpGaD
Plerixafor—CXCR4—HIF-1-alpha transcription factor network—TERT—cervical cancer	0.0155	0.0431	CbGpPWpGaD
Plerixafor—CXCR4—Class A/1 (Rhodopsin-like receptors)—TAAR6—cervical cancer	0.015	0.0416	CbGpPWpGaD
Plerixafor—CXCR4—GPCR ligand binding—TAAR6—cervical cancer	0.0114	0.0317	CbGpPWpGaD
Plerixafor—CXCR4—GPCR ligand binding—WNT2—cervical cancer	0.00891	0.0247	CbGpPWpGaD
Plerixafor—CXCR4—CXCR4-mediated signaling events—MTOR—cervical cancer	0.00826	0.023	CbGpPWpGaD
Plerixafor—CXCR4—CXCR4-mediated signaling events—CD4—cervical cancer	0.00825	0.0229	CbGpPWpGaD
Plerixafor—CXCR4—GPCR ligand binding—WNT5A—cervical cancer	0.00675	0.0187	CbGpPWpGaD
Plerixafor—CXCR4—GPCR downstream signaling—TAAR6—cervical cancer	0.00645	0.0179	CbGpPWpGaD
Plerixafor—CXCR4—CXCR4-mediated signaling events—STAT3—cervical cancer	0.00639	0.0177	CbGpPWpGaD
Plerixafor—CXCR4—Signaling by GPCR—TAAR6—cervical cancer	0.00585	0.0163	CbGpPWpGaD
Plerixafor—CXCR4—HIV Life Cycle—CD4—cervical cancer	0.00561	0.0156	CbGpPWpGaD
Plerixafor—CXCR4—Signaling by GPCR—WNT2—cervical cancer	0.00457	0.0127	CbGpPWpGaD
Plerixafor—CXCR4—GPCR downstream signaling—AKAP13—cervical cancer	0.00442	0.0123	CbGpPWpGaD
Plerixafor—CXCR4—Signaling by GPCR—AKAP13—cervical cancer	0.00401	0.0111	CbGpPWpGaD
Plerixafor—CXCR4—HIV Infection—CD4—cervical cancer	0.00387	0.0108	CbGpPWpGaD
Plerixafor—CXCR4—Disease—WNT2—cervical cancer	0.00386	0.0107	CbGpPWpGaD
Plerixafor—CXCR4—Signaling by GPCR—WNT5A—cervical cancer	0.00346	0.00962	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—TAAR6—cervical cancer	0.00346	0.0096	CbGpPWpGaD
Plerixafor—CXCR4—Disease—WNT5A—cervical cancer	0.00292	0.00811	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—WNT2—cervical cancer	0.0027	0.0075	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—AKAP13—cervical cancer	0.00237	0.00658	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—WNT5A—cervical cancer	0.00205	0.00568	CbGpPWpGaD
Plerixafor—CXCR4—Disease—HES1—cervical cancer	0.00168	0.00467	CbGpPWpGaD
Plerixafor—CXCR4—Disease—MTHFR—cervical cancer	0.00148	0.0041	CbGpPWpGaD
Plerixafor—CXCR4—Disease—TERT—cervical cancer	0.00147	0.00409	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—NOTCH2—cervical cancer	0.00144	0.00399	CbGpPWpGaD
Plerixafor—CXCR4—Disease—FGFR3—cervical cancer	0.00135	0.00375	CbGpPWpGaD
Plerixafor—CXCR4—Disease—NOTCH1—cervical cancer	0.00127	0.00353	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—HES1—cervical cancer	0.00118	0.00327	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—TERT—cervical cancer	0.00103	0.00287	CbGpPWpGaD
Plerixafor—CXCR4—Disease—MTOR—cervical cancer	0.000951	0.00264	CbGpPWpGaD
Plerixafor—CXCR4—Disease—CD4—cervical cancer	0.000949	0.00264	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—FGFR3—cervical cancer	0.000947	0.00263	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—NOTCH1—cervical cancer	0.000889	0.00247	CbGpPWpGaD
Plerixafor—CXCR4—Disease—CTNNB1—cervical cancer	0.000843	0.00234	CbGpPWpGaD
Plerixafor—CXCR4—Signaling by GPCR—EGFR—cervical cancer	0.000792	0.0022	CbGpPWpGaD
Plerixafor—CXCR4—Disease—STAT3—cervical cancer	0.000735	0.00204	CbGpPWpGaD
Plerixafor—CXCR4—Disease—EGFR—cervical cancer	0.000668	0.00186	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—MTOR—cervical cancer	0.000666	0.00185	CbGpPWpGaD
Plerixafor—Haemoglobin—Topotecan—cervical cancer	0.000614	0.0468	CcSEcCtD
Plerixafor—CXCR4—Signaling Pathways—CASP3—cervical cancer	0.000613	0.0017	CbGpPWpGaD
Plerixafor—Haemorrhage—Topotecan—cervical cancer	0.000611	0.0466	CcSEcCtD
Plerixafor—CXCR4—Signaling Pathways—CTNNB1—cervical cancer	0.000591	0.00164	CbGpPWpGaD
Plerixafor—Immune system disorder—Topotecan—cervical cancer	0.000552	0.042	CcSEcCtD
Plerixafor—CXCR4—Signaling Pathways—STAT3—cervical cancer	0.000515	0.00143	CbGpPWpGaD
Plerixafor—Ill-defined disorder—Topotecan—cervical cancer	0.000493	0.0376	CcSEcCtD
Plerixafor—Malaise—Topotecan—cervical cancer	0.000479	0.0365	CcSEcCtD
Plerixafor—CXCR4—Signaling Pathways—EGFR—cervical cancer	0.000468	0.0013	CbGpPWpGaD
Plerixafor—Arthralgia—Topotecan—cervical cancer	0.000453	0.0345	CcSEcCtD
Plerixafor—Unspecified disorder of skin and subcutaneous tissue—Topotecan—cervical cancer	0.00045	0.0343	CcSEcCtD
Plerixafor—Discomfort—Topotecan—cervical cancer	0.000447	0.0341	CcSEcCtD
Plerixafor—Anaphylactic shock—Topotecan—cervical cancer	0.000434	0.0331	CcSEcCtD
Plerixafor—Nervous system disorder—Topotecan—cervical cancer	0.000426	0.0324	CcSEcCtD
Plerixafor—Skin disorder—Topotecan—cervical cancer	0.000421	0.0321	CcSEcCtD
Plerixafor—Hyperhidrosis—Topotecan—cervical cancer	0.000419	0.032	CcSEcCtD
Plerixafor—Musculoskeletal discomfort—Topotecan—cervical cancer	0.000395	0.0301	CcSEcCtD
Plerixafor—CXCR4—Signaling Pathways—TP53—cervical cancer	0.000393	0.00109	CbGpPWpGaD
Plerixafor—Paraesthesia—Topotecan—cervical cancer	0.00039	0.0297	CcSEcCtD
Plerixafor—Dyspnoea—Topotecan—cervical cancer	0.000387	0.0295	CcSEcCtD
Plerixafor—Dyspepsia—Topotecan—cervical cancer	0.000382	0.0291	CcSEcCtD
Plerixafor—Gastrointestinal disorder—Topotecan—cervical cancer	0.000375	0.0286	CcSEcCtD
Plerixafor—Fatigue—Topotecan—cervical cancer	0.000374	0.0285	CcSEcCtD
Plerixafor—Pain—Topotecan—cervical cancer	0.000371	0.0283	CcSEcCtD
Plerixafor—Constipation—Topotecan—cervical cancer	0.000371	0.0283	CcSEcCtD
Plerixafor—Feeling abnormal—Topotecan—cervical cancer	0.000358	0.0273	CcSEcCtD
Plerixafor—Gastrointestinal pain—Topotecan—cervical cancer	0.000355	0.027	CcSEcCtD
Plerixafor—Urticaria—Topotecan—cervical cancer	0.000345	0.0263	CcSEcCtD
Plerixafor—Abdominal pain—Topotecan—cervical cancer	0.000343	0.0261	CcSEcCtD
Plerixafor—Hypersensitivity—Topotecan—cervical cancer	0.00032	0.0244	CcSEcCtD
Plerixafor—Asthenia—Topotecan—cervical cancer	0.000311	0.0237	CcSEcCtD
Plerixafor—Pruritus—Topotecan—cervical cancer	0.000307	0.0234	CcSEcCtD
Plerixafor—Diarrhoea—Topotecan—cervical cancer	0.000297	0.0226	CcSEcCtD
Plerixafor—Dizziness—Topotecan—cervical cancer	0.000287	0.0219	CcSEcCtD
Plerixafor—Vomiting—Topotecan—cervical cancer	0.000276	0.021	CcSEcCtD
Plerixafor—Rash—Topotecan—cervical cancer	0.000274	0.0209	CcSEcCtD
Plerixafor—Dermatitis—Topotecan—cervical cancer	0.000273	0.0208	CcSEcCtD
Plerixafor—Headache—Topotecan—cervical cancer	0.000272	0.0207	CcSEcCtD
Plerixafor—Nausea—Topotecan—cervical cancer	0.000258	0.0196	CcSEcCtD
